logo

Media

BPI signed a cooperation agreement with the University of Balamand in field of Biotechnology

 

BPI and IncellDx, Inc. Announce OEM and International Distribution Agreement for Single Cell Immuno-Oncology and Oncology Diagnostic Products in Middle East and North Africa (MENA)

10 May 2018

 

MENLO PARK, CA; BPI announced today that it has concluded an exclusive OEM and International Distribution agreement for IncellDx, Inc. (hereinafter referred to as “IncellDx”) single cell immune-oncology and oncology diagnostic products in the Middle East, North Africa (MENA). Products included in the agreement are IncellDx’s proprietary single cell quantification of Programmed Death Ligand 1 (PD-L1) on tumor cells and immune cell subtypes in Lung, Bladder, and Head & Neck cancer as well as single cell HPV E6/E7 mRNA detection for cervical cancer, and the IncellPREP® tissue single cell suspension system for solid tumors. BPI will be the first company to offer the quantitative PD-L1 assay with cell cycle using flow cytometric or circulating tumor cell (CTC) technology.

 

Bernard Tannoury, Chairman and CEO of BPI stated: “In collaboration with IncellDx, BPI will be able to provide the patient and healthcare community in the MENA region with regulatory approved revolutionary single cell quantitative, qualitative and fast diagnostics technology. We are thrilled to collaborate with IncellDx, an innovative and dynamic company and pair it with BPI’s extensive expertise in the healthcare field in the region; our partnership reaffirms BPI’s long standing commitment to improve the patient’s quality of life and delivers on BPI’s strategy to developing strong collaborations and vibrant partnerships.”

 

Dr. Bruce Patterson, CEO of IncellDx said: “We look forward to this exciting business venture with BPI, a leader in pharmaceuticals and biotechnology in the region. For the first time, our 3Dx technology used in all of our immune-oncology and oncology products which powerfully combines multiplex RNA in situ hybridization/quantification, multiplex protein quantification, and DNA cell cycle simultaneously in individual cells will be sold in this growth market. Our assay platform yields unparalleled amounts of information on every cell in a heterogeneous tumor environments to better serve the needs of the healthcare market and practitioners. This assay platform can be used on flow cytometers, fluorescence microscopes, and CTC machines commonly in diagnostic laboratories.”

 

About BPI

 

BPI, a leader in the healthcare and pharmaceutical industry is committed to improving human health and wellbeing through the manufacturing pharmaceutical products, medical devices as healthcare products including diagnostic and prognostic technology.

BPI has become a front runner in manufacturing enhanced formulations for the treatment of a wide range of diseases. It also produces oncology, biotech and sterile products.

BPI has earned a number of International, regional, and local certificates. The most important of these are the European Good Manufacturing Practice (GMP) and ISO 9001: 2008. Our medical devices also meet the highest standards of the European Union and have acquired the CE marking. BPI is expanding strategically with a presence in more than 40 countries. Headquartered in Lebanon, BPI has regional offices in Europe, the Gulf and Africa.

 

 

About IncellDx, Inc.

 

IncellDx, Inc,located at Menlo Park, California, USA is a single cell diagnostic company committed to advancing Precision Medicine by offering transformative diagnostic and prognostic clinical patient information based on an innovative technology platform that enables quantitative, simultaneous cell classification and single cell protein analysis, multiplex RNA in situ hybridization, and DNA cell cycle analysis. The Company develops products designed to address pressing unmet clinical needs in the advancement of cancer care in addition to its virology products.